SIRT1 and prostate carcinoma: We have previously identified SIRT1 as a positive regulator of epithelial-to-mesenchymal transition (EMT), cell invasion, and metastatic growth of prostate cancer cells, and put forward SIRT1 as a potential therapeutic target to reverse EMT and to prevent prostate cancer progression (8,19).